Atara biotherapeutics to host ebv and ms day

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, will host an ebv and multiple sclerosis (ms) day on tuesday, march 22, 2022 from 4:00 – 6:00 p.m. edt. dr. pascal touchon, president and chief executive officer along with other members of the atara management team,
ATRA Ratings Summary
ATRA Quant Ranking